Last reviewed · How we verify

NCT03386760: PicoS

Evaluation of an Ultra-speed Picosecond Laser for Treating Tattoos

Completed Phase 1, PHASE2 Last updated 22 July 2024
What this trial tests

Phase 1, PHASE2 trial testing Laser Utilisation PicoSecond in Tattoo; Pigmentation in 18 participants. Completed in 8 July 2022.

Timeline
15 January 2018
Primary endpoint
8 July 2022
8 July 2022

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nice
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment18
Start date15 January 2018
Primary completion8 July 2022
Estimated completion8 July 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nice

Who can join

Adults 18 to 75, any sex, with Tattoo; Pigmentation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The investigators developed an ultra-speed picosecond laser (20ps) with a 20gHz repetition rate that provide very promising results in vitro and in ex vivo skin to remove skin tattoos. The aim of this study is to evaluate the efficacy and tolerance of a new ultra-speed picosecond laser and to compare it to a nanosecond laser for treating black tattoos. In a first phase of the study 10 patients with black tattoos will be treated with increasing fluencies of the picosecond laser to the optimal parameters in terms of efficacy and tolerance. In a second phase, 10 additional subjects with black tattoos will be treated after central randomization on half of the tattoo with the picosecond laser (with the parameters determined in the first phase) and the other half treated with a nanosecond laser.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tattoo; Pigmentation

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nice trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03386760.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing